๐ŸŽFREE MT2 VIAL WITH ELIGIBLE ORDERS โ€” $60 VALUE ยท LIMITED TIME
Home Products COA Library Research Insights About FAQ My Account
Products / Tirzepatide
RESEARCH USE ONLY

Tirzepatide 10mg

$89.95 $89.95 / vial
AUSTRALIA'S TRUSTED CHOICE โœฆโœฆโœฆโœฆโœฆ
Select Strength
FREE MT2 VIAL WITH ELIGIBLE ORDERS Complimentary $60 value ยท Claim in cart ยท While stocks last ยท Research use only
Bundle quantity
Same-day dispatch Orders placed before 2pm AEST on business days
Australia Post Standard 2โ€“5 business days ยท Express 1โ€“3 business days ยท Free Express shipping on orders over $100
Shipment protection included Lost or damaged in transit? We replace it, no questions asked.
Pay in 4 with afterpay Interest-free instalments over 6 weeks. Afterpay is available on our secure payment page. Select "Place Order" at checkout to view your available payment methods. Eligibility and terms apply.
ACCEPTED PAYMENT METHODS
VISA mastercard AMERICAN
EXPRESS
Overview

HALO BIO ยท COMPOUND RESEARCH PROFILE
Tirzepatide 10mg
Dual GIP & GLP-1 receptor research

Explore the molecular structure of tirzepatide, its dual incretin receptor activity and published investigations into glucose regulation, metabolic signalling and body-weight outcomes.

Tirzepatide is a synthetic 39-amino-acid peptide designed to activate two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It has been studied extensively in metabolic and endocrine research.

Halo Bio supplies Tirzepatide 10mg-labelled lyophilised research material. The 10mg quantity represents the nominal product specification and is not a batch-specific measurement of identity, purity or content.

PRODUCT & RESEARCH SNAPSHOT

Tirzepatide at a glance

Scientific name: Tirzepatide
Classification: Dual GIP and GLP-1 receptor agonist
Peptide chain: 39 amino acids
Molecular formula: C225H348N48O68
Molecular weight: Approximately 4,813.53 g/mol
Structural characteristic: Modified peptide with a fatty diacid side-chain attachment
Labelled strength: 10mg per vial
Presentation: Lyophilised laboratory research material
Research areas: Incretin receptor signalling, glucose metabolism, appetite regulation and metabolic outcomes
Fulfilment: Melbourne-held stock ยท eligible same-day dispatch before 2pm

MOLECULAR RESEARCH

Understanding dual incretin signalling

Tirzepatide is distinguished by its activity at both the GIP and GLP-1 receptors. These receptors participate in metabolic signalling and the regulation of glucose-dependent insulin responses.

PATHWAY 01

GIP receptor activity

The GIP receptor participates in glucose-dependent insulin signalling. Researchers investigate its contribution to metabolic regulation and interactions with GLP-1 pathways.

PATHWAY 02

GLP-1 receptor activity

GLP-1 receptor signalling is associated with glucose-dependent insulin secretion, glucagon regulation, appetite-related pathways and gastric motility.

PATHWAY 03

Metabolic research

Clinical research using approved formulations has examined blood-glucose markers, body weight, cardiometabolic measurements and metabolic signalling.

Published clinical outcomes apply to studied pharmaceutical formulations and populations. They do not demonstrate equivalent effects from Halo Bio research material.

PUBLISHED SCIENTIFIC EVIDENCE

What have tirzepatide studies investigated?

Tirzepatide has been evaluated in large randomised clinical trials examining type 2 diabetes and obesity. The trials used pharmaceutical formulations manufactured and administered under controlled clinical protocols.


Jastreboff et al. ยท SURMOUNT-1 (2022)

A 72-week randomised study involving 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, investigated changes in body weight. Mean reductions in the treatment-regimen analysis were 15.0%, 19.5% and 20.9% in the three tirzepatide treatment groups, compared with 3.1% for placebo.


Frรญas et al. ยท SURPASS-2 (2021)

A 40-week randomised trial compared pharmaceutical tirzepatide with semaglutide in adults with type 2 diabetes receiving metformin. Researchers evaluated glycated haemoglobin (HbA1c), body weight and other clinical outcomes.


Pharmacological and receptor research

Mechanistic investigations have characterised tirzepatide’s dual receptor activity, peptide structure and pharmacological properties. Its fatty diacid side-chain contributes to albumin binding and prolonged exposure in studied formulations.

The clinical findings above are not purity, safety or performance claims for Halo Bio’s separately supplied 10mg research vial.

MOLECULAR COMPARISON

Tirzepatide vs Semaglutide

Both compounds have been investigated in incretin-related metabolic research, but they differ in molecular structure and receptor pharmacology.

Characteristic Tirzepatide Semaglutide
Receptor activity GIP and GLP-1 GLP-1
Peptide chain 39 amino acids 31 amino acids
Structural feature Modified GIP-based peptide with lipid side-chain Modified GLP-1 analogue with lipid side-chain
Research context Dual incretin signalling GLP-1 signalling

These are distinct compounds. Research findings for one should not be transferred to the other without supporting evidence.

AUSTRALIAN FULFILMENT

Melbourne stock. Nationwide dispatch.

Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is provided during fulfilment, with delivery times dependent on destination and carrier.

FREQUENTLY ASKED QUESTIONS

Tirzepatide research FAQs

What is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide with dual GIP and GLP-1 receptor agonist activity.

What does dual incretin activity mean?

It refers to activity at both GIP and GLP-1 receptors, which participate in glucose-dependent insulin signalling and metabolic regulation.

What is Tirzepatide studied for?

Published studies have examined glucose regulation, HbA1c, weight-related outcomes and incretin receptor signalling.

Is Tirzepatide the same as Semaglutide?

No. Tirzepatide activates GIP and GLP-1 receptors, whereas semaglutide is a GLP-1 receptor agonist. Their molecular structures differ.

What does the 10mg vial label mean?

It refers to the nominal labelled quantity of research material in the vial. It does not by itself verify measured content or purity.

Is this product the same as Mounjaro or Zepbound?

No. Those are regulated prescription medicine formulations containing tirzepatide. Halo Bio’s lyophilised research vial is a separate material and is not interchangeable with those products.

Do clinical trial findings apply to this vial?

No direct equivalence can be assumed. Clinical outcomes concern specific pharmaceutical formulations, defined study populations and controlled protocols.

Has this Halo Bio batch been independently tested?

Batch-specific analytical results should be established using documentation identifying the actual tested material. A nominal label quantity or unrelated supplier’s report does not establish batch purity.

Is it suitable for human or animal use?

No. Halo Bio supplies this material for laboratory research only, not for consumption, injection, self-administration or clinical treatment.

When will my order be dispatched?

Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day after payment confirmation.

SCIENTIFIC REFERENCES

Independent scientific publications

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
    Read publication โ†—
  2. Frรญas JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
    Read publication โ†—
  3. US Food and Drug Administration. Zepbound (tirzepatide) prescribing information.
    View documentation โ†—
  4. PubChem. Tirzepatide, Compound CID 156588324.
    View molecular data โ†—

Laboratory research use only.

Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published clinical findings concern regulated pharmaceutical formulations and do not establish identity, purity, sterility, safety or performance of this separately supplied research material.

Order total $89.95